Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Chedid M, Chebib F, Dahlen E, Mueller T, Schnell T, Gay M, Hommos M, Swaminathan S, Garg A, Mao M, Amberg B, Baldares K, Johnson K, Bishop A, Vaughn J, Hogan M, Torres V, Chaudhry R, Zoghby Z
An Electronic Health Record–Integrated Application for Standardizing Care and Monitoring Patients With Autosomal Dominant Polycystic Kidney Disease Enrolled in a Tolvaptan Clinic: Design and Implementation Study
Standardizing care and monitoring ADPKD patients enrolled in a Tolvaptan clinic using an intelligent automated electronic health record application
Maroun Chedid;
Fouad Chebib;
Erin Dahlen;
Theodore Mueller;
Theresa Schnell;
Melissa Gay;
Musab Hommos;
Sundararaman Swaminathan;
Arvind Garg;
Michael Mao;
Brigid Amberg;
Kirk Baldares;
Karen Johnson;
Alyssa Bishop;
Jackqueline Vaughn;
Marie Hogan;
Vicente Torres;
Rajeev Chaudhry;
Ziad Zoghby
ABSTRACT
Background:
Tolvaptan is the only FDA-approved drug to slow the progression of autosomal dominant polycystic kidney disease (ADPKD), but its use requires strict clinical monitoring due to potential serious adverse events.
Objective:
We share our experience in developing and implementing an electronic health record (EHR) based application to efficiently monitor patients with ADPKD initiated on Tolvaptan.
Methods:
The application was developed in collaboration with clinical informatics based on our clinical protocol with frequent laboratory monitoring to detect early drug-related toxicity. The application streamlines clinical workflow and enables our nursing team to take appropriate actions in real-time to prevent drug-related serious adverse events. We retrospectively analyzed the characteristics of enrolled patients.
Results:
As of September 2022, 214 patients were enrolled in the Tolvaptan program across all Mayo Clinic sites. Of these, 126 were enrolled in the “Tolvaptan monitoring application” and 88 in the “Past Tolvaptan patients’ application”. The mean age at enrollment was 43.1±9.9 years. The two EHR-based applications allow consolidation of all necessary patient information and real-time data management at the individual or population level. This approach ensures efficient staff workflow, monitoring of drug-related adverse events, and timely prescription renewal.
Conclusions:
Our study demonstrates the feasibility of integrating digital applications into the EHR workflow, facilitating efficient and safe care delivery for patients enrolled in a drug monitoring program. This workflow can be extended to other healthcare systems for similar programs of chronic disease management, to ensure that all eligible patients can safely receive the best available treatment for their condition. Clinical Trial: N/A
Citation
Please cite as:
Chedid M, Chebib F, Dahlen E, Mueller T, Schnell T, Gay M, Hommos M, Swaminathan S, Garg A, Mao M, Amberg B, Baldares K, Johnson K, Bishop A, Vaughn J, Hogan M, Torres V, Chaudhry R, Zoghby Z
An Electronic Health Record–Integrated Application for Standardizing Care and Monitoring Patients With Autosomal Dominant Polycystic Kidney Disease Enrolled in a Tolvaptan Clinic: Design and Implementation Study